User profiles for Jun O. Liu

Jun O. Liu

Johns Hopkins School of Medicine
Verified email at jhu.edu
Cited by 30865

[HTML][HTML] Recent advances in drug repositioning for the discovery of new anticancer drugs

JS Shim, JO Liu - International journal of biological sciences, 2014 - ncbi.nlm.nih.gov
Drug repositioning (also referred to as drug repurposing), the process of finding new uses of
existing drugs, has been gaining popularity in recent years. The availability of several …

Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP

Y Liu-Chittenden, B Huang, JS Shim… - Genes & …, 2012 - genesdev.cshlp.org
The Drosophila TEAD ortholog Scalloped is required for Yki-mediated overgrowth but is largely
dispensable for normal tissue growth, suggesting that its mammalian counterpart may be …

Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin

…, S Bhat, WC Merrick, R Green, B Shen, JO Liu - Nature chemical …, 2010 - nature.com
Although the protein synthesis inhibitor cycloheximide (CHX) has been known for decades,
its precise mechanism of action remains incompletely understood. The glutarimide portion of …

Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth

…, D Chang, R Pili, CV Dang, JO Liu… - Proceedings of the …, 2008 - National Acad Sciences
A library of drugs that are in clinical trials or use was screened for inhibitors of hypoxia-inducible
factor 1 (HIF-1). Twenty drugs inhibited HIF-1-dependent gene transcription by >88% at …

Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization

…, H Zhang, DZ Qian, S Rey, JO Liu… - Proceedings of the …, 2009 - National Acad Sciences
HIF-1 is a heterodimeric transcription factor that mediates adaptive responses to hypoxia
and plays critical roles in cancer progression. Using a cell-based screening assay we have …

[PDF][PDF] Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth

…, KS Chang, M Fereshteh, D Gardner, T Reya, JO Liu… - Cancer cell, 2010 - cell.com
In a screen of drugs previously tested in humans we identified itraconazole, a systemic
antifungal, as a potent antagonist of the Hedgehog (Hh) signaling pathway that acts by a …

XPB, a subunit of TFIIH, is a target of the natural product triptolide

…, PS Miller, JF Kugel, JA Goodrich, JO Liu - Nature chemical …, 2011 - nature.com
Triptolide ( 1 ) is a structurally unique diterpene triepoxide isolated from a traditional Chinese
medicinal plant with anti-inflammatory, immunosuppressive, contraceptive and antitumor …

[PDF][PDF] Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin

…, S Chen, YH Chang, Z Wu, K Biemann, JO Liu - Chemistry & biology, 1997 - cell.com
Background: Angiogenesis, the formation of new blood vessels, is essential for tumor growth.
The inhibition of angiogenesis is therefore emerging as a promising therapy for cancer. …

Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells

…, DZ Qian, S Rey, H Wei, JO Liu… - Proceedings of the …, 2009 - National Acad Sciences
Using a cell-based reporter gene assay, we screened a library of drugs in clinical use and
identified the anthracycline chemotherapeutic agents doxorubicin and daunorubicin as potent …

A three-hybrid system for detecting small ligand–protein receptor interactions

EJ Licitra, JO Liu - Proceedings of the National Academy of …, 1996 - National Acad Sciences
Small ligand–receptor interactions underlie many fundamental processes in biology and
form the basis for pharmacological intervention of human diseases in medicine. We report …